Fabrication of an Immunosensor for Quantitative Detection of Breast Cancer Biomarker UBE2C

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 May 6

PMID 35516403

Authors

V S P K Sankara Aditya Jayanthi

Asim Bikas Das

Urmila Saxena

Affiliations

Soon will be listed here.

Abstract

This work reports the design of a new electrochemical impedimetric immunosensor for the direct determination of ubiquitin-conjugating enzymes 2C (UBE2C), a potential diagnostic biomarker for breast cancer. The immunosensor was fabricated by immobilizing the capture anti-UBE2C antibody onto a polyaniline (PANI) modified glassy carbon electrode (GCE) through glutaraldehyde crosslinking. The assembly process of the immunosensor was examined using scanning electron microscopy, cyclic voltammetry, and electrochemical impedance spectroscopy. The fabricated immunosensor enabled the detection of recombinant human UBE2C in the range of 500 pg mL to 5 μg mL. The limit of detection and limit of quantification were found to be 7.907 pg mL and 26.356 pg mL, respectively. The diagnostic application of the fabricated immunosensor was explored for the analysis of breast cancer cell line MCF-7 cell extract. The immunosensor demonstrated high selectivity for UBE2C. The fabricated immunosensor also exhibited good reproducibility and storage stability.

Citing Articles

Electrochemical and Optical Carbon Dots and Glassy Carbon Biosensors: A Review on Their Development and Applications in Early Cancer Detection.

Lopez J, Munoz M, Arias V, Garcia V, Calvo P, Ondo-Mendez A Micromachines (Basel). 2025; 16(2).

PMID: 40047624 PMC: 11857277. DOI: 10.3390/mi16020139.

Advancements in biosensors for cancer detection: revolutionizing diagnostics.

Mustafa S, Khan M, Sagheer M, Kumar D, Pandey S Med Oncol. 2024; 41(3):73.

PMID: 38372827 DOI: 10.1007/s12032-023-02297-y.

Fluorescence immunosensor based on functional nanomaterials and its application in tumor biomarker detection.

Huang J, Wei F, Cui Y, Hou L, Lin T RSC Adv. 2022; 12(48):31369-31379.

PMID: 36349017 PMC: 9624183. DOI: 10.1039/d2ra04989a.

Performance of electrochemical immunoassays for clinical diagnostics of SARS-CoV-2 based on selective nucleocapsid N protein detection: Boron-doped diamond, gold and glassy carbon evaluation.

Bialobrzeska W, Ficek M, Dec B, Osella S, Trzaskowski B, Jaramillo-Botero A Biosens Bioelectron. 2022; 209:114222.

PMID: 35430407 PMC: 8989705. DOI: 10.1016/j.bios.2022.114222.

References

Zhang J, Liu X, Yu G, Liu L, Wang J, Chen X . UBE2C Is a Potential Biomarker of Intestinal-Type Gastric Cancer With Chromosomal Instability. Front Pharmacol. 2018; 9:847. PMC: 6082955. DOI: 10.3389/fphar.2018.00847. View

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

Bajaj S, Alam S, Roy K, Datta A, Nath S, Roychoudhury S . E2 Ubiquitin-conjugating Enzyme, UBE2C Gene, Is Reciprocally Regulated by Wild-type and Gain-of-Function Mutant p53. J Biol Chem. 2016; 291(27):14231-14247. PMC: 4933179. DOI: 10.1074/jbc.M116.731398. View

Zhao L, Jiang L, Wang L, He J, Yu H, Sun G . UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer. J Cancer Res Clin Oncol. 2012; 138(11):1951-61. DOI: 10.1007/s00432-012-1275-2. View

Mo C, Gao L, Zhu X, Wei K, Zeng J, Chen G . The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data. Cancer Cell Int. 2017; 17:83. PMC: 5613379. DOI: 10.1186/s12935-017-0455-1. View

Fujita T, Ikeda H, Taira N, Hatoh S, Naito M, Doihara H . Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer. BMC Cancer. 2009; 9:87. PMC: 2666760. DOI: 10.1186/1471-2407-9-87. View

Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C, Ricolleau G . Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. Br J Cancer. 2009; 101(1):166-73. PMC: 2713693. DOI: 10.1038/sj.bjc.6605122. View

Shuliang S, Lei C, Guangwu J, Changjie L . Involvement of ubiquitin-conjugating enzyme E2C in proliferation and invasion of prostate carcinoma cells. Oncol Res. 2014; 21(3):121-7. DOI: 10.3727/096504013X13832473329953. View

Berlingieri M, Pallante P, Sboner A, Barbareschi M, Bianco M, Ferraro A . UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer. 2007; 43(18):2729-35. DOI: 10.1016/j.ejca.2007.09.003. View

10.

Hao Z, Zhang H, Cowell J . Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumour Biol. 2011; 33(3):723-30. DOI: 10.1007/s13277-011-0291-1. View

11.

Qin T, Huang G, Chi L, Sui S, Song C, Li N . Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1. Biomed Pharmacother. 2017; 95:649-655. DOI: 10.1016/j.biopha.2017.08.095. View

12.

Rawat A, Gopal G, Selvaluxmy G, Rajkumar T . Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole. Cell Oncol (Dordr). 2013; 36(6):459-67. DOI: 10.1007/s13402-013-0150-8. View

13.

Chou C, Huang N, Jhuang S, Pan H, Peng N, Cheng J . Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions. PLoS One. 2014; 9(4):e93934. PMC: 3974821. DOI: 10.1371/journal.pone.0093934. View

14.

Jin J, Li X, Gygi S, Harper J . Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature. 2007; 447(7148):1135-8. DOI: 10.1038/nature05902. View

15.

Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K . Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 2007; 121(1):33-8. DOI: 10.1002/ijc.22605. View

16.

Xie C, Powell C, Yao M, Wu J, Dong Q . Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker. Int J Biochem Cell Biol. 2013; 47:113-7. DOI: 10.1016/j.biocel.2013.11.023. View

17.

Ma R, Kang X, Zhang G, Fang F, Du Y, Lv H . High expression of UBE2C is associated with the aggressive progression and poor outcome of malignant glioma. Oncol Lett. 2016; 11(3):2300-2304. PMC: 4774622. DOI: 10.3892/ol.2016.4171. View

18.

Martinez-Canales S, Lopez de Rodas M, Nuncia-Cantarero M, Paez R, Amir E, Gyorffy B . Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer. Cancer Med. 2018; 7(5):1896-1907. PMC: 5943485. DOI: 10.1002/cam4.1406. View

19.

Dhand C, Das M, Datta M, Malhotra B . Recent advances in polyaniline based biosensors. Biosens Bioelectron. 2010; 26(6):2811-21. DOI: 10.1016/j.bios.2010.10.017. View

20.

Jiang L, Huang C, Lu Y, Luo C, Hu G, Liu H . Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors. Brain Res. 2008; 1201:161-6. DOI: 10.1016/j.brainres.2008.01.037. View